NanoPhoria develops non-viral, nano-delivery systems for inhalable biologics targeting cardiovascular conditions. This technology enhances the bioavailability of therapeutic agents, improving treatment efficacy while minimizing invasive procedures.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for cardiovascular conditions often require invasive procedures and systemic drug delivery, leading to potential side effects and limited bioavailability of therapeutic agents in the targeted tissues. Effective delivery of biologics to the cardiovascular system remains a significant challenge.
Solution
NanoPhoria is developing a non-viral, nano-in-micro delivery system for inhalable biologics designed to treat cardiovascular conditions. This innovative approach aims to enhance the bioavailability of therapeutic agents directly to the lungs, providing a non-invasive route for targeted drug delivery. By utilizing nano-carriers encapsulated within microparticles, the technology protects the biologics during inhalation and facilitates their efficient absorption into the pulmonary circulation. This method has the potential to improve treatment efficacy while minimizing systemic exposure and the need for invasive procedures. The inhalable delivery system offers a more convenient and patient-friendly alternative to traditional cardiovascular treatments.
Target Audience
The primary target audience includes patients with cardiovascular conditions requiring biologic therapies, as well as pharmaceutical companies seeking innovative drug delivery methods.
Features
- Non-viral nano-delivery system for biologics
- Inhalable formulation for direct lung delivery
- Nano-in-micro particle technology for enhanced bioavailability
- Targeted delivery to the pulmonary circulation
- Protection of biologics during inhalation